The cause of death in mTNBC patients with BM is rarely due to progressive intracranial lesions alone, in our study 29% (37/127), in contrast to HER2-positive breast cancer patients with BM, a setting in which up to 50% of patients die of progressive BM disease [12]. Here, ERBB2 is linked to breast cancer.